View Older Stories View More Recent Stories

Oct 19, 2021 06:45AM Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk
Oct 4, 2021 09:00AM Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals
Sep 30, 2021 06:09AM Lilly's (LLY) tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study
Sep 30, 2021 04:40AM Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study
Sep 30, 2021 04:30AM Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study
Sep 28, 2021 06:32AM Lilly (LLY) will lower list price of Insulin Lispro Injection in U.S. by additional 40 percent effective January 1,
Sep 28, 2021 06:30AM Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options
Sep 9, 2021 08:01AM Eli Lilly & Co. (LLY) Announces FDA grants Jardiance Breakthrough Therapy designation for heart failure with preserved ejection fraction
Sep 9, 2021 08:00AM FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction
Sep 7, 2021 09:00AM Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to "Type 1 Diabetes Camps Initiative"
Aug 27, 2021 11:25AM Lilly (LLY) announces trial demonstrates Jardiance is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Aug 27, 2021 11:25AM Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Aug 18, 2021 01:31PM Lilly (LLY) Announces US FDA approves Jardiance to treat adults living with heart failure with reduced ejection fraction
Aug 18, 2021 01:30PM US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
Aug 16, 2021 07:02AM Eli Lilly & Co. (LLY) Announces FDA approves Lyumjev 100 units/mL for use in insulin pumps
Aug 16, 2021 07:00AM FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps
Jul 6, 2021 06:27AM Eli Lilly & Co. (LLY) Confirms Breakthrough Heart Failure Trial Results
Jul 6, 2021 06:25AM Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
Jun 26, 2021 04:15PM Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes
Jun 25, 2021 11:39AM Lilly's (LLY) SURPASS-2 results published in NEJM show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
Jun 25, 2021 11:30AM Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 di
Jun 24, 2021 08:00AM Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin
May 20, 2021 06:46AM Lilly's (LLY) tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial
May 20, 2021 06:45AM Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial
May 12, 2021 04:05PM American Resources Corporation Reports First Quarter 2021 Financial Results and Provides Business Outlook
May 6, 2021 06:45AM Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes
Mar 31, 2021 08:30AM Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
Mar 25, 2021 03:50PM Pfizer (PFE), Lilly (LLY) Announce Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
Mar 25, 2021 03:50PM Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
Mar 4, 2021 06:49AM Lilly's (LLY) Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
Mar 4, 2021 06:45AM Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
Feb 25, 2021 06:45AM Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions
Feb 17, 2021 06:51AM Lilly (LLY) announces Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from SURPASS program
Feb 17, 2021 06:45AM Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
Jan 19, 2021 06:35AM Lilly (LLY) and Merus NV (MRUS) Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Jan 19, 2021 06:30AM Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Jan 11, 2021 09:23AM Pre-Open Stock Movers 01/11: (MESO) (LLY) (WBAI) Higher; (MARA) (RIOT) (MSTR) Lower (more...)
Jan 11, 2021 08:00AM US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
Dec 9, 2020 06:45AM Lilly's (LLY) tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
Dec 9, 2020 06:45AM Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
Dec 4, 2020 08:00AM Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19
Nov 19, 2020 06:56AM Eli Lilly & Co. (LLY), Ypsomed (YPSN) Report Collaboration to Advance an Automated Insulin Delivery System for People with Diabetes
Nov 19, 2020 06:45AM Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Nov 18, 2020 08:00AM Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Oct 23, 2020 10:46AM Lilly (LLY) announces new Jardiance findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of CKD status
Oct 23, 2020 10:45AM New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
Oct 7, 2020 06:32AM Lilly (LLY) and Dexcom (DXCM) partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring
Oct 7, 2020 06:30AM Lilly and Dexcom team up on new program to help improve diabetes management
Oct 7, 2020 12:06AM Trump says catching COVID-19 was 'blessing from God'
Sep 22, 2020 09:29AM Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multipl
View More Recent Stories View Older Stories